MESO-Rx
Anabolic Steroids
Hair Loss
- Thread starter billydidit
- Start date
IronBrothers
New Member
Ive been using some nizoral for a couple months 2x a wk. No noticeable slowing of shedding... every time I shower I see like 10+ hairs in my towel. Mostly short ones coming from my temples... should I use it every day?
Marcinska M, Pospiech E, Abidi S, Andersen JD, van den Berge M, et al. Evaluation of DNA Variants Associated with Androgenetic Alopecia and Their Potential to Predict Male Pattern Baldness. PLoS One. 2015;10(5):e0127852. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0127852
Androgenetic alopecia, known in men as male pattern baldness (MPB), is a very conspicuous condition that is particularly frequent among European men and thus contributes markedly to variation in physical appearance traits amongst Europeans.
Recent studies have revealed multiple genes and polymorphisms to be associated with susceptibility to MPB. In this study, 50 candidate SNPs for androgenetic alopecia were analyzed in order to verify their potential to predict MPB.
Significant associations were confirmed for 29 SNPs from chromosomes X, 1, 5, 7, 18 and 20. A simple 5-SNP prediction model and an extended 20-SNP model were developed based on a discovery panel of 305 males from various European populations fitting one of two distinct phenotype categories. The first category consisted of men below 50 years of age with significant baldness and the second; men aged 50 years or older lacking baldness.
The simple model comprised the five best predictors: rs5919324 near AR, rs1998076 in the 20p11 region, rs929626 in EBF1, rs12565727 in TARDBP and rs756853 in HDAC9. The extended prediction model added 15 SNPs from five genomic regions that improved overall prevalence-adjusted predictive accuracy measured by area under the receiver characteristic operating curve (AUC).
Both models were evaluated for predictive accuracy using a test set of 300 males reflecting the general European population. Applying a 65% probability threshold, high prediction sensitivity of 87.1% but low specificity of 42.4% was obtained in men aged <50 years. In men aged >/=50, prediction sensitivity was slightly lower at 67.7% while specificity reached 90%.
Overall, the AUC=0.761 calculated for men at or above 50 years of age indicates these SNPs offer considerable potential for the application of genetic tests to predict MPB patterns, adding a highly informative predictive system to the emerging field of forensic analysis of externally visible characteristics.
Androgenetic alopecia, known in men as male pattern baldness (MPB), is a very conspicuous condition that is particularly frequent among European men and thus contributes markedly to variation in physical appearance traits amongst Europeans.
Recent studies have revealed multiple genes and polymorphisms to be associated with susceptibility to MPB. In this study, 50 candidate SNPs for androgenetic alopecia were analyzed in order to verify their potential to predict MPB.
Significant associations were confirmed for 29 SNPs from chromosomes X, 1, 5, 7, 18 and 20. A simple 5-SNP prediction model and an extended 20-SNP model were developed based on a discovery panel of 305 males from various European populations fitting one of two distinct phenotype categories. The first category consisted of men below 50 years of age with significant baldness and the second; men aged 50 years or older lacking baldness.
The simple model comprised the five best predictors: rs5919324 near AR, rs1998076 in the 20p11 region, rs929626 in EBF1, rs12565727 in TARDBP and rs756853 in HDAC9. The extended prediction model added 15 SNPs from five genomic regions that improved overall prevalence-adjusted predictive accuracy measured by area under the receiver characteristic operating curve (AUC).
Both models were evaluated for predictive accuracy using a test set of 300 males reflecting the general European population. Applying a 65% probability threshold, high prediction sensitivity of 87.1% but low specificity of 42.4% was obtained in men aged <50 years. In men aged >/=50, prediction sensitivity was slightly lower at 67.7% while specificity reached 90%.
Overall, the AUC=0.761 calculated for men at or above 50 years of age indicates these SNPs offer considerable potential for the application of genetic tests to predict MPB patterns, adding a highly informative predictive system to the emerging field of forensic analysis of externally visible characteristics.
Wessagowit V, Tangjaturonrusamee C, Kootiratrakarn T, Bunnag T, Pimonrat T, et al. Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract. Australas J Dermatol. http://onlinelibrary.wiley.com/doi/10.1111/ajd.12352/abstract
BACKGROUND/OBJECTIVES: Male androgenetic alopecia (AGA) is a common hair problem. Serenoa repens extract has been shown to inhibit both types of 5-alpha reductase and, when taken orally, has been shown to increase hair growth in AGA patients. The aim of this study was to assess the efficacy of topical products containing S. repens extract for the treatment of male AGA.
METHODS: This was a pilot, prospective, open, within-subject comparison limited to 24 weeks using no placebo controls. In all, 50 male volunteers aged between 20 and 50 years received topical S. repens products for 24 weeks. The primary end-point was a hair count in an area of 2.54 cm2 at week 24. Secondary end-points included hair restoration, investigators' photographic assessment, patients' evaluation and discovering adverse events.
RESULTS: The average hair count and terminal hair count increased at weeks 12 and 24 compared to baseline. Some of these positive results levelled off at week 24, presumably because the concentrated topical product containing S. repens extract was stopped after 4 weeks. The patients were satisfied with the products and the side-effects were limited.
CONCLUSIONS: The topical application of S. repens extract could be an alternative treatment in male pattern baldness in male patients who do not want or cannot tolerate the side-effects of standard medications, but the use of a concentrated S. repens product beyond 4 weeks may be necessary for sustained efficacy.
BACKGROUND/OBJECTIVES: Male androgenetic alopecia (AGA) is a common hair problem. Serenoa repens extract has been shown to inhibit both types of 5-alpha reductase and, when taken orally, has been shown to increase hair growth in AGA patients. The aim of this study was to assess the efficacy of topical products containing S. repens extract for the treatment of male AGA.
METHODS: This was a pilot, prospective, open, within-subject comparison limited to 24 weeks using no placebo controls. In all, 50 male volunteers aged between 20 and 50 years received topical S. repens products for 24 weeks. The primary end-point was a hair count in an area of 2.54 cm2 at week 24. Secondary end-points included hair restoration, investigators' photographic assessment, patients' evaluation and discovering adverse events.
RESULTS: The average hair count and terminal hair count increased at weeks 12 and 24 compared to baseline. Some of these positive results levelled off at week 24, presumably because the concentrated topical product containing S. repens extract was stopped after 4 weeks. The patients were satisfied with the products and the side-effects were limited.
CONCLUSIONS: The topical application of S. repens extract could be an alternative treatment in male pattern baldness in male patients who do not want or cannot tolerate the side-effects of standard medications, but the use of a concentrated S. repens product beyond 4 weeks may be necessary for sustained efficacy.
Goose
New Member
Just started rogain, will report results in 6 months.
IronBrothers
New Member
I was going to buy some tonight too. Amazon has like 12month supply of generic 2% for like 60bucks. Only problem is it doesnt help the receding hairline by the temples and in front.. thats where mines getting bad.
Goose
New Member
I wouldn't do the 2%. Go for 5%. The the 2% is for balding women. You can get the equate brand at Walmart for 3 months it's $18.
IronBrothers
New Member
Shit sry I meant 5%. The kirkland brand for like $27 6month supply. Got confused with the nizoral 2% im using.
Goose
New Member
Well I'm giving it 6 months with the equate. If it don't work I'm only out $40 bucks... I thinned out in the front from a cycle I did 5 years ago. It stopped falling out just never grew back. I've seen reviews where it worked for some people on frontal balding. We shall see!!!
ironwill1951
New Member
IronBrothers
New Member
If you stop using it doesnt it leave you worse off than when you started?
blazinshotguns
New Member
Stop using what ?
IronBrothers
New Member
Rogaine
blazinshotguns
New Member
I used rogaine propecia nizoral for a whole year. Restored myself to a Norwood 1 . Stopped rogaine and no difference . Stopped propecia and started losing hair like crazy, so stopping rogaine didn't cause any loss for me
Hu R, Xu F, Sheng Y, Qi S, Han Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. http://onlinelibrary.wiley.com/doi/10.1111/dth.12246/abstract
Finasteride at 1 mg/day and 5% topical minoxidil are effective in male androgenetic alopecia (MAGA). However, studies describing their effects in Chinese individuals are scarce.
450 Chinese MAGA patients were randomly assigned to receive finasteride (n = 160), minoxidil (n = 130) and combined medication (n = 160) for 12 months.
The patients returned to the clinic every 3 months for efficacy evaluation. And efficacy was evaluated in 428 men at treatment end, including 154, 122, and 152 in the finasteride, 5% minoxidil, and combination groups, respectively.
All groups showed similar baseline characteristics, including age at enrollment, and duration and severity of alopecia (p > 0.05).
At 12 months, 80.5, 59, and 94.1% men treated with finasteride, 5% minoxidil and the combination therapy showed improvement, respectively. Adverse reactions were rare (finasteride, 1.8%; minoxidil, 6.1%), and disappeared right after drug withdrawal.
In conclusion, finasteride is superior to 5% minoxidil, while the combined medication showed the best efficacy.
Finasteride at 1 mg/day and 5% topical minoxidil are effective in male androgenetic alopecia (MAGA). However, studies describing their effects in Chinese individuals are scarce.
450 Chinese MAGA patients were randomly assigned to receive finasteride (n = 160), minoxidil (n = 130) and combined medication (n = 160) for 12 months.
The patients returned to the clinic every 3 months for efficacy evaluation. And efficacy was evaluated in 428 men at treatment end, including 154, 122, and 152 in the finasteride, 5% minoxidil, and combination groups, respectively.
All groups showed similar baseline characteristics, including age at enrollment, and duration and severity of alopecia (p > 0.05).
At 12 months, 80.5, 59, and 94.1% men treated with finasteride, 5% minoxidil and the combination therapy showed improvement, respectively. Adverse reactions were rare (finasteride, 1.8%; minoxidil, 6.1%), and disappeared right after drug withdrawal.
In conclusion, finasteride is superior to 5% minoxidil, while the combined medication showed the best efficacy.
battletested71
New Member
Thanks for the info!
At 44 years old my first cycle was 26 years ago.
Straight sustanon 500mg ew
5 years later i did it again. Both cycles were 8 weeks.
Later in my life I did a test/win cycle for 12 weeks.
at 39 i did another cyle of 50mg var ed, 50mg tbol ed , 600mgtest ew for 12 weeks.
At 40 same cycle
at 41 same cycle
at 42:
600mg test E
300mg deca
50 mg var
50 mg anadrol
24 week cycle.
I have not had any hair loss and I have a full head of long black hair. Hairloss is largely genetics. Yes it will speed it up but I know over a dozen longterm users that all have their hair and they are all heavy users...if you're meantto lose then you're gonna losel.
I'm just sharing this information so some of you dont panic if youre not already losing hair.....if you are....the above mentiones is phenominal information!
Great info and thanks for posting!
Up to 60% people suffer from hair loss throughout their lifetime.
Hair growth undergoes recurrent cycling of growth, regression, and resting phases with a defined periodicity.
The main cause of human hair loss is due to the premature transition from growth to regression.
Understanding of the molecular basis underlying hair regression is important to elucidate the mechanisms of hair loss.
Here, we demonstrated that miR-22, a highly conserved microRNA, is critical for the transition from growth to regression of the hair follicle.
Importantly, miR-22 could be a novel target for therapeutic therapy of hair loss disorders.
Yuan S, Li F, Meng Q, Zhao Y, Chen L, et al. Post-transcriptional Regulation of Keratinocyte Progenitor Cell Expansion, Differentiation and Hair Follicle Regression by miR-22. PLoS Genet. 2015;11(5):e1005253. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1005253
Hair follicles (HF) undergo precisely regulated recurrent cycles of growth, cessation, and rest.
The transitions from anagen (growth), to catagen (regression), to telogen (rest) involve a physiological involution of the HF. This process is likely coordinated by a variety of mechanisms including apoptosis and loss of growth factor signaling.
However, the precise molecular mechanisms underlying follicle involution after hair keratinocyte differentiation and hair shaft assembly remain poorly understood. Here we demonstrate that a highly conserved microRNA, miR-22 is markedly upregulated during catagen and peaks in telogen.
Using gain- and loss-of-function approaches in vivo, we find that miR-22 overexpression leads to hair loss by promoting anagen-to-catagen transition of the HF, and that deletion of miR-22 delays entry to catagen and accelerates the transition from telogen to anagen.
Ectopic activation of miR-22 results in hair loss due to the repression a hair keratinocyte differentiation program and keratinocyte progenitor expansion, as well as promotion of apoptosis.
At the molecular level, we demonstrate that miR-22 directly represses numerous transcription factors upstream of phenotypic keratin genes, including Dlx3, Foxn1, and Hoxc13.
We conclude that miR-22 is a critical post-transcriptional regulator of the hair cycle and may represent a novel target for therapeutic modulation of hair growth.
Hair growth undergoes recurrent cycling of growth, regression, and resting phases with a defined periodicity.
The main cause of human hair loss is due to the premature transition from growth to regression.
Understanding of the molecular basis underlying hair regression is important to elucidate the mechanisms of hair loss.
Here, we demonstrated that miR-22, a highly conserved microRNA, is critical for the transition from growth to regression of the hair follicle.
Importantly, miR-22 could be a novel target for therapeutic therapy of hair loss disorders.
Yuan S, Li F, Meng Q, Zhao Y, Chen L, et al. Post-transcriptional Regulation of Keratinocyte Progenitor Cell Expansion, Differentiation and Hair Follicle Regression by miR-22. PLoS Genet. 2015;11(5):e1005253. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1005253
Hair follicles (HF) undergo precisely regulated recurrent cycles of growth, cessation, and rest.
The transitions from anagen (growth), to catagen (regression), to telogen (rest) involve a physiological involution of the HF. This process is likely coordinated by a variety of mechanisms including apoptosis and loss of growth factor signaling.
However, the precise molecular mechanisms underlying follicle involution after hair keratinocyte differentiation and hair shaft assembly remain poorly understood. Here we demonstrate that a highly conserved microRNA, miR-22 is markedly upregulated during catagen and peaks in telogen.
Using gain- and loss-of-function approaches in vivo, we find that miR-22 overexpression leads to hair loss by promoting anagen-to-catagen transition of the HF, and that deletion of miR-22 delays entry to catagen and accelerates the transition from telogen to anagen.
Ectopic activation of miR-22 results in hair loss due to the repression a hair keratinocyte differentiation program and keratinocyte progenitor expansion, as well as promotion of apoptosis.
At the molecular level, we demonstrate that miR-22 directly represses numerous transcription factors upstream of phenotypic keratin genes, including Dlx3, Foxn1, and Hoxc13.
We conclude that miR-22 is a critical post-transcriptional regulator of the hair cycle and may represent a novel target for therapeutic modulation of hair growth.
purepotency101
New Member
Big help to me thanks
Understanding images: microRNAs contribute to hair loss and follicle regression
http://blogs.plos.org/biologue/2015...tribute-to-hair-loss-and-follicle-regression/
http://blogs.plos.org/biologue/2015...tribute-to-hair-loss-and-follicle-regression/
Similar threads
Sponsors
Latest posts
-
-
-
Sigma Audley Inc. - Your source for peptides, ancillaries, AAS, and more!- Latest: Trenbolonetax
-
-
TrenboloneTax: Hybrid Cycling / Lifting Log aka Make Hulk Bike Fast
- Latest: Trenbolonetax